| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Virology, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas 77025
As a part of a program directed toward the elucidation of the role of viruses in mouse and human breast cancer, a variety of immunological techniques were applied to a study of the humoral immune response of mice and of humans to their breast tumors. Tumor-bearing mice were found to produce antibodies against a complex array of tumor cell-associated antigens, including mouse mammary tumor virus (MMTV), components, heterophile and Forssman-like antigens, embryonic antigens, and possibly other tumor-associated antigens. Mice bearing MMTV-positive tumors had high titer antibodies against both viral and heterophile antigens. Tumor-free mice, whether of high or low mammary cancer strains, were remarkably free of antibodies that could label MMTV particles, although some sera contained antibodies to viral components.
Patients with breast cancer also had antibodies against a variety of antigens associated with their own and homologous breast cancer cells. These antibodies reacted with heterophile, embryonic, and other tumor-associated antigens, some of which appeared to be viral. Sera of some patients with breast cancer gave positive immunofluorescence reactions with mouse mammary tumor cells grown in tissue culture and producing MMTV. Most of these reactions were due to heterophile antibodies in the sera, but a small number of sera contained antibodies apparently directed specifically toward MMTV particles, as determined by immunoperoxidase electron microscopy. Although human-mouse cross-reactions must be interpreted with caution, these data suggest that a virus putatively associated with human breast cancer is antigenically related to MMTV.
1 Presented at the symposium "Immunological Control of Virus-associated Tumors in Man: Prospects and Problems," April 7 to 9, 1975, Bethesda, Md. This research was supported in part by Contracts NO 1 CP 43370 and NO 1 CP 33304 within the Virus Cancer Program of the National Cancer Institute, by Grant CA 05831 from the National Cancer Institute, USPHS, and by Grant RRO-5511 from the Division of Research Resources, NIH.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |